Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of July 2018, specifically dated July 2, 2018. The report serves to disclose two press releases regarding regulatory milestones for the company's immuno-oncology pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of corporate events rather than a financial statement.
Material Changes and Corporate Events
- COM701 IND Clearance: The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for COM701, described as a first-in-class immuno-oncology therapeutic antibody.
- Bayer Collaboration: The FDA cleared Bayer's IND application for BAY 1905254, a compound associated with Compugen's technology platform.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the regulatory approvals. The primary focus is the advancement of clinical development programs.
Investor Verification Checklist
- Verify the clinical trial design and enrollment status for COM701 following FDA clearance.
- Confirm the terms of the collaboration with Bayer regarding BAY 1905254 and potential milestone payments.
- Review the company's cash runway and capital requirements to support the initiation of these clinical trials.